Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Director · President and CEO | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date August 25, 2026 · Filed August 27, 2026
Jointly reported with Masson Kristina
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,230,052 |
Reported balance
After 2026-08-25 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-25 · Sale · Disposed 14,036 · Balance 2,230,052 F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2: The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4. F3: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 385,859 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 385,859 F4: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2: The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4.
F3: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F4: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2026 Filed Aug 27, 2026 20:14 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 14,036 | $2.21 | $30,969.03 |
DisclosureSEC source: 0000905148-26-003968 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,230,052 F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · price: The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4. F3 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:07 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 484 | $2.01 | $972.84 |
DisclosureSEC source: 0000905148-26-003836 · form4.xml · nonDerivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 385,859 F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:07 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 1,229 | $2.01 | $2,470.29 |
DisclosureSEC source: 0000905148-26-003836 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,244,088 F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:09 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 13,729 | $1.79 | $24,574.91 |
DisclosureSEC source: 0000905148-26-002652 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,245,317 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:29 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 72,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002549 · form4.xml · nonDerivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 386,343 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:29 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 180,095 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002549 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,259,046 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:10 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 490 | $1.92 | $940.80 |
DisclosureSEC source: 0000905148-26-002498 · form4.xml · nonDerivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 313,637 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:10 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 1,253 | $1.92 | $2,405.76 |
DisclosureSEC source: 0000905148-26-002498 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,078,951 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:15 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 185,495 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000905148-26-001115 · form4.xml · derivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 185,495 Underlying: Common Stock · 185,495 shares Expires 2036-02-29 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:15 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 417,210 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000905148-26-001115 · form4.xml · derivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,210 Underlying: Common Stock · 417,210 shares Expires 2036-02-29 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| February 21, 2026 Filed Feb 24, 2026 21:12 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 14,265 | $1.53 | $21,825.45 |
DisclosureSEC source: 0000905148-26-001010 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,080,204 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:09 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 579 | $1.63 | $943.77 |
DisclosureSEC source: 0000905148-26-000934 · form4.xml · nonDerivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 314,127 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen?s spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:09 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 1,302 | $1.63 | $2,122.26 |
DisclosureSEC source: 0000905148-26-000934 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,094,469 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson?s spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| January 14, 2026 Filed Jan 16, 2026 21:02 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | PurchaseCommon Stock | 49,000 | $1.68 | $82,124.00 |
DisclosureSEC source: 0000905148-26-000226 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,095,771 F1 · price: The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.66 to $1.68, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:03 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 19,904 | $2.30 | $45,779.20 |
DisclosureSEC source: 0000905148-25-004179 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,046,771 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:28 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 490 | $2.24 | $1,097.60 |
DisclosureSEC source: 0000905148-25-004127 · form4.xml · nonDerivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 314,706 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:28 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 59,765 | $2.24 | $133,873.60 |
DisclosureSEC source: 0000905148-25-004127 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,066,675 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| August 21, 2025 Filed Aug 25, 2025 20:39 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 19,905 | $1.32 | $26,274.60 |
DisclosureSEC source: 0000905148-25-003121 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,126,440 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 21:14 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 490 | $1.39 | $681.10 |
DisclosureSEC source: 0000905148-25-003039 · form4.xml · nonDerivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 315,196 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 21:14 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 59,766 | $1.39 | $83,074.74 |
DisclosureSEC source: 0000905148-25-003039 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,146,345 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:58 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 19,904 | $1.15 | $22,889.60 |
DisclosureSEC source: 0000905148-25-001900 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,206,111 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:16 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 491 | $1.14 | $559.74 |
DisclosureSEC source: 0000905148-25-001820 · form4.xml · nonDerivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 315,686 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:16 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 59,766 | $1.14 | $68,133.24 |
DisclosureSEC source: 0000905148-25-001820 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,226,015 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:11 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 140,540 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0000905148-25-000828 · form4.xml · derivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 140,540 Underlying: Common Stock · 140,540 shares Expires 2035-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:11 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 390,390 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0000905148-25-000828 · form4.xml · derivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,390 Underlying: Common Stock · 390,390 shares Expires 2035-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:09 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 19,904 | $5.54 | $110,268.16 |
DisclosureSEC source: 0000905148-25-000764 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,285,781 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:52 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 579 | $5.42 | $3,138.18 |
DisclosureSEC source: 0000905148-25-000725 · form4.xml · nonDerivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 316,177 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:52 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 37,152 | $5.42 | $201,363.84 |
DisclosureSEC source: 0000905148-25-000725 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,305,685 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:29 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 19,910 | $6.44 | $128,220.40 |
DisclosureSEC source: 0000905148-24-003270 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,342,837 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 21:26 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 490 | $7.92 | $3,880.80 |
DisclosureSEC source: 0000905148-24-003223 · form4.xml · nonDerivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 316,756 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 21:26 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 59,766 | $7.92 | $473,346.72 |
DisclosureSEC source: 0000905148-24-003223 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,362,747 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:11 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 79,616 | $9.19 | $731,671.04 |
DisclosureSEC source: 0000905148-24-002335 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,422,513 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:47 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 59,765 | $7.02 | $419,550.30 |
DisclosureSEC source: 0000905148-24-002277 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,502,129 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 14, 2024 Filed May 16, 2024 22:54 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 54,918 | $8.36 | $459,114.48 |
DisclosureSEC source: 0000905148-24-001483 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,561,894 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Nov 27, 2024 23:04 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 90,090 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000905148-24-003287 · form4.xml · derivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 90,090 Underlying: Common Stock · 90,090 shares Expires 2034-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. F3 · ownership.nature: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 01, 2024 Filed Nov 27, 2024 23:04 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 225,226 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000905148-24-003287 · form4.xml · derivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO Masson Kristina · CIK 0001950501 · Director · EVP - Business Operations Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,226 Underlying: Common Stock · 225,226 shares Expires 2034-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. F2 · ownership.direct: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:06 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 41,861 | $3.40 | $142,327.40 |
DisclosureSEC source: 0000905148-24-000760 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,616,812 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:41 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 239,023 | $5.08 | $1,214,236.84 |
DisclosureSEC source: 0000905148-23-001472 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,658,673 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:19 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 493,994 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-000783 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,897,696 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 00:40 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,605 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001140361-23-027860 · form4.xml · derivative · entry 3 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,855 Underlying: Common Stock · 33,605 shares Expires 2032-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested or shall vest quarterly on the last day of each quarter for 16 quarters following January 1, 2022, in each case subject to the Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The expiration date for these options was inadvertently reported as April 5, 2032 on the Form 3 filed by the Reporting Person on November 9, 2022, and has been corrected as of this Form 4. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 00:40 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Exercise / conversionCommon Stock | 33,605 | $3.88 | $130,387.40 |
DisclosureSEC source: 0001140361-23-027860 · form4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,403,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:05 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 80,120 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0001209191-22-057395 · doc4.xml · derivative · entry 6 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 80,120 Underlying: Common Stock · 80,120 shares Expires 2032-11-13 F6 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. F5 · ownership.nature: These securities are held by Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:05 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 180,269 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0001209191-22-057395 · doc4.xml · derivative · entry 5 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,269 Underlying: Common Stock · 180,269 shares Expires 2032-11-13 F6 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:05 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 26,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057395 · doc4.xml · nonDerivative · entry 4 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 320,705 F4 · kind: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · ownership.nature: These securities are held by Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:05 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 60,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057395 · doc4.xml · nonDerivative · entry 3 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370,097 F3 · kind: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:05 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 503,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057395 · doc4.xml · nonDerivative · entry 2 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,310,007 F2 · kind: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. This RSU grant to the Reporting Person constitutes a number of shares equal to 1.885% of the total outstanding shares of the Issuer as of the pricing of the Issuer's initial public offering, on a fully diluted basis after giving effect to the offering, meant to cover estimated tax liability at the time of settlement of the RSU award referred to in footnote 1. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:05 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 934,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057395 · doc4.xml · nonDerivative · entry 1 Blume-Jensen Peter · CIK 0001950499 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,806,588 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. This RSU grant to the Reporting Person constitutes a number of shares equal to 3.5% of the total outstanding shares of the Issuer as of the pricing of the Issuer's initial public offering, on a fully diluted basis after giving effect to the offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.